Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 9, 2022
- Annualized Bleeding Rate (ABR) Reduced by 85% from Baseline, Demonstrating Superiority to Factor VIII ProphylaxisBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the...
-
Jan 4, 2022- Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 6 at 11:00am ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January. To access the...
Dec 16, 2021BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today...
-
Dec 15, 2021
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to...
-
Nov 30, 2021- Multiple Innovative Programs in a Variety of Indications to be Discussed by BioMarin Management and External Speakers
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021. BioMarin management and external experts will provide...